<SEC-DOCUMENT>0001144204-19-029251.txt : 20191021
<SEC-HEADER>0001144204-19-029251.hdr.sgml : 20191021
<ACCEPTANCE-DATETIME>20190531162913
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001144204-19-029251
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20190531

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MONOGRAM ORTHOPAEDICS INC
		CENTRAL INDEX KEY:			0001769759
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				812349540
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		53 BRIDGE STREET UNIT 507
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11201
		BUSINESS PHONE:		(718) 576-3205

	MAIL ADDRESS:	
		STREET 1:		53 BRIDGE STREET UNIT 507
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11201
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="tv522685_logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">May 31, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Amanda Ravitz</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Assistant Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Office of Electronics and Machinery</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Division of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Washington DC 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left">Re:</TD><TD STYLE="text-align: justify">Monogram Orthopaedics, Inc.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Offering Statement on Form 1-A</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Filed March 13, 2019</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in">File No. 024-10973</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">Dear Ms. Ravitz,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We acknowledge receipt of comments in your letter of April 9, 2019
regarding the Offering Statement of Monogram Orthopaedics, Inc. (the &ldquo;Company&rdquo;), which we have set out below, together
with our responses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"><U>Form 1-A filed March 13, 2019</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"><U>Investors in this offering may not be entitled to a jury
trial, page 11</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: left">We note your disclosure in this risk factor that investors
 &quot;should consult legal counsel regarding the jury waiver provision before entering into the subscription agreement.&quot;
However, we note that section 9 of the subscription agreement states that each party represents and warrants that it &quot;has
reviewed this waiver with its legal counsel, and that it knowingly and voluntarily waives its jury trial rights following consultation
with legal counsel.&quot; Please revise to describe in an appropriate section of your offering circular this representation and
warranty included in the subscription agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
Company has revised the disclosure in the Risk Factors and Plan of Distribution sections of the offering circular to describe
this representation and warranty included in the subscription agreement.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"><U>Provisions of Note in Our Subscription Agreement, page
16</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: left">Section 9 of your subscription agreement appears to indicate
that the forum selection provision does not apply to actions arising under the federal securities laws. If so, please revise page
16 of your offering circular to disclose that your exclusive forum provision does apply to actions arising under the federal securities
laws. Also, please tell us which exhibit represents the operating agreement mentioned on page 16.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left"><I>The Company has revised the disclosure on page 16
of the offering circular to disclose that the exclusive forum provision contained in the subscription agreement does not apply
to actions arising under the federal securities laws. In addition, the Company has removed the reference to the operating agreement
mentioned on page 16, as this was made in error.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"><U>Use of Proceeds to Issuer, page 17</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: left">We note your disclosure on page 10 regarding investors
paying the purchase price for your shares by cancellation or conversion of indebtedness. Please quantify the price per share that
investors who cancel or convert debt as mentioned on page 10 will pay per share for the securities being offered in this transaction,
and highlight any difference in the price that other investors will pay. Also, tell us the portion of the offering that would
be sold if all eligible debt holders cancelled or converted their debt for securities in this offering. In this regard, if your
disclosures regarding the minimum offering amount like on pages 24 and 25 are based on the assumption that there are no note cancellations
or conversions, please clarify those disclosures in context.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0; margin-left: 0.5in"><I>The Company has amended its offering circular to clarify
that investors will not be able to acquire shares in the Offering by cancellation of indebtedness. The outstanding indebtedness
of the Company consists of convertible promissory notes which may convert into the equity securities of the Company upon the contractual
terms of such notes. The dilutive effect of these conversions is described in the &ldquo;Dilution&rdquo; section of the offering
circular. Additionally, the Company has amended the disclosure in the &ldquo;Use of Proceeds&rdquo; section and elsewhere in the
offering circular to make it clear that the shares pursuant to this Offering may only be purchased with new funds rather than the
cancellation of indebtedness.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.8pt; text-indent: -35.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: left">We note exhibit 6.1 and your disclosure regarding accounts
payable to related parties like on page F-18. Please provide the disclosure required by instruction 2 to Form 1-A Part II Item
6. Also, ensure that the appropriate section of your offering circular includes all disclosure required by Form 1-A Part II Items
10, 11 and 13, including with regard to section 6(c) of exhibit 6.9.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.8pt; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0in; text-align: left"><I>The Company has amended the offering
circular to provide the necessary disclosure in regard to exhibits 6.1 and 6.9. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"><U>The Company's Business, page 18</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: left">Given the status of development of your product, please
tell us the basis for your statements on page 20 regarding the equipment being significantly cheaper and your flexibility to discount.
Also clarify which of the disclosed capabilities and advantages of the product have been developed and objectively demonstrated,
and clarify any material disadvantages identified to date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0in; text-align: left"><I>The Company has revised its disclosure
in the &ldquo;Company&rsquo;s Business&rdquo; section of the offering circular to provide further explanation of why the Company
believes it will be able to offer its equipment at a significantly cheaper price. The Company has also removed the statement in
regards to its flexibility to discount.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.8pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.8pt; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.8pt; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0in"><I>The Company has also added disclosure
to clarify which of the disclosed capabilities and advantages of the product have been developed and objectively demonstrated,
and clarify any material disadvantages identified to date.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.8pt; text-indent: -35.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">6.</TD><TD STYLE="text-align: justify">Please tell us whether you commissioned any of the data
cited in your offering circular. We note for example the information on page 25.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.8pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><I>The Company has amended its disclosure to identify
the study and report which it commissioned. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in"><U>Regulation, page 22</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">7.</TD><TD STYLE="text-align: justify">Please reconcile the timeline disclosed in the last sentence
in this section with the timeline disclosed in the first sentence of the second bullet point on page 25, particularly given the
twelve months mentioned in the last bullet point on page 24.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><I>The Company has revised its disclosure
in the offering circular to clarify that it expects to submit to the FDA its 510(k) premarket notification submission within 3
years of the closing of the offering, and expects approval by the FDA within 12 months of this submission. As such, the Company
expects FDA approval of its 510(k) premarket notification within 4 years of the closing of the offering.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"><U>Exhibits</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">8.</TD><TD STYLE="text-align: justify">Please file, or tell us why you do not believe you are required to file, the license
                                                                            agreement mentioned in the second risk factor on page 9, the preemptive rights mentioned on page 11, the agreements mentioned
                                                                            in footnote (1) on page 29, the development and supply agreement mentioned in the third paragraph on page 30, the warrants
                                                                            mentioned on pages 30 and F-18, and the notes mentioned on page F-12 not identified in your exhibit index. Also, please tell
                                                                            us (1) the authority on which you rely to offer new, substituted or additional securities as indicated on page 13 of exhibit
                                                                            4 and (2) whether the subscription agreement mentioned on page 16 is the same document as the Series A Preferred Stock
                                                                            Purchase Agreement mentioned on page 16.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><I>The Company has included 1-A/A submission the license
agreement mentioned on page 9 as Exhibit 6.17. The preemptive rights mentioned on page 11 are part of this agreement.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.8pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><I>In regard to the agreements mentioned in footnote
(1) on page 29, the Company has included the Restricted Stock Purchase Agreement for Dr. Unis as Exhibit 6.15 as it falls under
6(c) of Form 1-A Part III Item 17. The Company does not intend to file the Restricted Stock Purchase Agreements for Mr. Somani,
Mr. Dicicco, or Mr. Costa as these individuals are not officers or directors of the Company for 6(c) of Form 1-A Part III Item
17, nor would they be includable under 6(a) or 6(b) of that Item. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.8pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0; margin-left: 0.5in"><I>The
Company has included the development and supply agreement mentioned in the third paragraph on page 30 as Exhibit 6.19, as well
as the warrants agreement as Exhibit 6.20.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.8pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.8pt"><I></I></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.8pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><I>The Company acknowledges the comment regarding the
notes mentioned on page F-12 and believes that each note required to be included as an exhibit under Item 6 of Form 1-A Part III
Item 17 has been included.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><I>The Company notes that it has amended its Subscription
Agreement to remove the provision regarding the continued effectiveness of the Subscription Agreement following a stockholder approved
reorganization of the company resulting in the issuance of substituted or additional securities. Instead, this provision has been
incorporated into a new Investors&rsquo; Rights Agreement to clarify that the certain rights provided to investors will remain
in effect following any such reorganization. The Company intends for any issuance required by a stockholder approved reorganization
will be conducted in compliance with the registration requirements of the Securities Act of 1933 or an exemption thereunder. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.8pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><I>The reference to a Series A Preferred Stock Purchase
Agreement mentioned on page 16 was in error, and refers to the Subscription Agreement. The Company has revised this reference for
clarity.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Thank you again for the opportunity to respond to your questions
to the Offering Statement of Monogram Orthopaedics, Inc. If you have additional questions or comments, please contact me at andrew@crowdchecklaw.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 43%">Sincerely,</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><I>/s/ Andrew Stephenson</I></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Andrew Stephenson</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Partner</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>CrowdCheck Law LLP</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">cc: Benjamin Sexson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Monogram Orthopaedics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">53 Bridge Street, Unit 507</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Brooklyn, New York, 11251</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tv522685_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv522685_logo.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ 8@#E P$1  (1 0,1 ?_$ +X  0 " @,! 0
M       &!P4( @,$ 0D! 0 " P$!               #! $"!08'$  ! P(#
M P<'!@D%$0$    " 0,$  41$@8A,0=!43(3,S0(87$B8A0U-H&10E)C%:'!
M<I(C@T06-['ALG.S\-&"PO)#4Y.CPX2T)45E%R<8$0 " 0($ P8$ P<% 0
M     0(1 R$Q$@1!,@51<8$B$S/P84(CH10TL<'14G*"!I'A\6)#-?_:  P#
M 0 "$0,1 #\ VHH!0"@% * 4 H!0"@% * \URN4"V0'Y]PD-Q8<85<?D.D@@
M IRJJT2J&Z&N7$'Q42C>=A:)CBTP*J*W>6.8B\K3*[!3F4_FJY;VG\Q5N;C@
MBL?_ +'KXE>$;M>VR5?2%#2.F/(G0:3=4_VX$7GD<EX+\7(V$@-.S!)/20FB
M;4TPV[A/-C6?7@^)CT99G?;.)_%[0TP(C\R8PC>S[MNK9FVJ)R(+R9D3\DJU
M=J$LD95R<2_>%WB(T]JQUJU7=L;/?7/1: BQC/ES-&NT27ZI?(JU5N[=QQ6*
M+-N^I=Y;R57)A0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% <7' ; C,D
M !12(B7!$1-JJJT!ISQHXJW/7VHDLMG5P[!'>1F!%:15*6]CE1TA3I9E[,>1
M-N^NC8LJ*JRE=FY.B+6X2^'*SV>.Q=]7L!<+R:(86\\"C1EWHA#N=/GQ]%.3
MGJO=W+EE@B:W82Q9.M5<7^'&CS]BN%S;24TF7[OABKS@(G(H-^B'F)4J.-J4
ML4;RN1B1B-XI>%[SPMN?>$82WO.QL03SY#,OP5M^6F:J_$F,BZ<-M;:9DRI$
MB!>+$T!'*-Q1(611,5(L<#:5$\RU'247\S>L9(TJU!%M4B]721I=B1^[\9W-
M&-Y<S@-8X"1%L5,5VCRHF^NBKJC2,WYI%169R3E%>6/$V2\.O&!_4,9=+7Y[
MK+U#;S091KZ4E@-XDO*XWS\J;>1:J;BSIQ61-9NUP>9>-5BP* 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4!4_B3U@[8.'QPHIJ$V^.>Q 2;%1G!2?5/.*9
M?EJ?;0U2(;\J1*[\*^@&)DV7K&<TAMP#6+:Q),4Z]1Q==3R@)(*>=:FW5SZ4
M1;:'$DGB)XQ3;!AI'3SZLW1]M'+E-!?38:/HM@O(9IM5>1//6FVLZO,S>_=I
M@C5Q54B4B52(EQ(EVJJKO556N@BFV?*&#W6>+<ILOV"WD:',3JWA$E$2;1<5
MZS#>*88[:K[F_"U!SEP+.UVT[]Q6XYLD>JI<2RVX-,6PL53 [G(3>9KMRK_>
M^2N-TZS+<7/S%SNBOEVG>ZM>CM;/Y6UWS?S["/Z=OL[3]]@7J"2C*M[P/MX<
MJ"OI"OD(<16N_..I4/-1='5'Z 6FYQKI:X=RC+C'FLMR&E]5T4)/Y:Y#5#I)
MU53UU@R* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * UA\7<TRU!IZ#BO5M1'
MG\O)F<<0,?\ 9U>V:S94W+R+>X"6YF#PFT\+2)C(9*2XN&&)O.$:_-CA5:_*
MLV3VE2)I_KF\O7K65[NCQ*92IKY"J\@":B";>1 %$KI6HTBBC-UD8/%%W+4E
M#18G)MIQUP&FQ4W#5! !VJJKL1$K6<E%5>2Q9M;BY-*.;P18C3$?1.GBDN93
MO<U,H)OP7?E3U0WKSK7DI7)=1W&E>S$]O"W'I>U<GC?F5XZZXZZ;KI*;CBJ1
MFN]57:JK7K(14519'B;DW-UDZMG"MC4W:X!3BF<)-/F:JI,M.1U5>9EXP3YD
M1*Y5]4FSH6GY46%41(* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * UD\7=O<
M&\Z<N.7]$Y'?C*?K-F)HGS&M7MF\T5-TLBUO#_=FKAPFL63#/# X;J)R$RX2
M?A'!:K7U23)[3K$U-XA623IS7]ZMQCU91IKCC&*;%;<+K6B1%WHHDE="'F@4
MVW"=246P;%J^PN,*PU$N+2)UJM (D)_1<'##$"Y4KR.Y]?8WJU<K;?PCW.U6
MWZCMG%Q4;B[%^)\TGI)NQ _=KPH(\QGZO;B+8#L4_P HN2L]3ZG+=-6K.4OV
MCI/2%M$[U^FJ/[.T@^I+\_>KHY+/$64]".TOT6TW?*N]:])T_91V]O2N.9Y+
MJ>_EN;KDW@LC%U>.>*&#=[@1;C@<)]/-&.4W6"D$B_;N$XB_FDE<J^ZS9T;2
M\J)]41(* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * K/Q":+>U/P\DE$;5RX
MV@DGQ1%,2(014>!/.VJKYTJ6Q*DB*]&J*@\,'$6/9[U(TK<'4;A7@T=@.&N
MA+1,N3;NZT43#RHG/5K=VZ^9$&WG3 LGCUP:=UE%;OEC 4U%";R$RJY4E,IM
M0,5V(8KT57S5!8O:71Y$MZUJQ69JO&?O&F[UBXTY$N$4E%^*^) 6'T@,5P7!
M:L[C;0W%MPEBF1[3>7-M<4XX-9]QG=9:V"[Q&(<)";CD(N2T+8JG_H_*@_AK
MD]*Z0[,W.>+X'<ZSUS\Q;4+>$?J_@1EBV7*1"D3V(KSL&)E]JE !$TWF7 <Y
MHF5,5KO.23H>;TNAYJR:F8T?IF;JC4UOL,,55V<\(&2?0:3:ZXOD$$5:TN3T
MJIM&+;H;^P(4>#!CPHPY(\5H&60Y@;%!%/F2N0W5U.FL#OH!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0!=J*F^@H:D<>N#<K2]T>U-86273TISK7@:QQA/
M$N/)N;(MHE]%=G-5_;WTUI93O6J.J)7PH\2\<8[-FUPXH.-HC;%\05(2%$P1
M)(CM0O71-O+SUI>VS6,3:W?63+FN&G>'VN83<F7$@7R.2?HY0Y'%1%3Z+H+F
M3YZJIRB3T4C"Q^ ?"-A[K1TZR1(N*"XX\8I_@D:I\];N_/M,>E%<#W:HU)PT
MT;878%V=A0K>K9!]T-@"DZ))@H#&!,2S>:M8QE)X&7))8FE-\6T3M124TU#D
M,VZ2]A;H+B]:^B$N @F7?MW)M7RK74C51\QSY8O VJX!\'BT=;3O-Y;3]X[B
M"(K>Q?96%V]4B_7)=IX>:N??O:G19%VU:TJI;U0$PH!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@.#S##[1M/-BZTX*@XV:(0D*[%0A78J+0%#\0/"U:K
MB\[/TA)&UR#52*VOXE%5?LR3$VO-M3S5:M[IK"17N;>N14$OA+QETQ)(HUKG
M@J+WBUN$X*X<N+!9N3E2K/JVY$#MS1UD''><A1B34CZ+TFE]LPV>>GVEV&*3
M,KI[PZ<4;[)1V?&&TLN+BY*N#F9W_5@IN*OGPK$MS&.1M&Q)YFP?#7@?I/0Y
M#,;%;E>\N!7.0B8ACO1EO:C:>7?Y:I7+[E@686E$L9-E1$HH!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0#!*4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * @NC)<M[B#K=AY]QQB.]#2.T9D0-H3&*H JN X\N
M%37(I0CXE6S)NY-=Q.JA+1X[R1#:)I"2B0L.J)(N"HJ NU*CNND7W$EE5FD^
MU$+X02Y4FVW I+[CY"\""KAD:HF3DS*M<WI%R4X2JZXG:_R"Q"W=BH*BTE@5
MUC@B@% * 4!7'%B9,CS+0,>0XRAJ>=&S(,?2'?E5,:XW5+LHRA0]%T+;V[D;
MFI5HBQ Z(^:NPCSISK(-?_$M>[U;M3:/;M]PDPVWS-'PCO.-"?Z9I/30%1"V
M+RU:VT4TZD%^5&C8"JI.* 4 H!0#%* KQ;_K#5MWG1=+2&+59+8ZL9^\.M>T
M./OBGIBPVJH&4?K+4VF,56694USF_+@D973\3B) O21+O+C7FRN-J27% 2-)
M:<3<!-CB)H7/6LG%K# W@KBECBB*:9O_ !*UC'F,P)L>TL0)DB._=381UQU1
M<7JVVFM@H@!AF)=ZU+<A"'SP(+5VY<K3!)YF<O.I-4R[\WI'31,_>42.V]>K
MU(#,TPAIZ*"TFPG#WX;DK2,(TU2R)9W).6B.?%GFNB<4-+Q#O!W1C4L&,BN3
MX!1AC/=4FTR8,%5,13;@M96B6%*&L_5@JUU'KONMI3$K2%W@/">FKV\,>8A
MF9%D!BP6;>.!;%2L1M5JGFC:Y>HXM<K.?%35=\L=MAQ]/@+M[G.FK+9"A_H8
M[:NOEE7U4PK%B"DVY9#=77!>7-F3DZPACH ]5M$BL^P+,;3?Z:AB@_G^C6JM
M^?22.ZE;U?(P<K66H;7I/3[;K 7'6-_$ C1L.J:ZPQZPS<0>B#0JF-;JTG)_
MRHB=Z481PK*1V+8>+C;7M0:FAO3$3,MO*$@Q25-N1'$7K$YLU-5O^7\1HO9Z
MOP,1PKNTJ7JC6UQN45;?*1R+[;&)<W5FRT0G@O*/HXIY*VW%(PCXFNTK*Y*J
MQP/HZAUMJZXOA87/8;>PO:8H."+T5,\"527?@->96YO[B35ORQ7$]K^3VNS@
MG?6N<N!E[,SKIB'>&+\8NPVHSJ-.G@1F2@N"@288CAOS59LQOJ,E<>"3H4=U
M+:RG!V4TVU4A^AV=7RX4J%8'1BM*8N291+E5%RX""+@2_,E<S81O.+C;?B=W
MJSVT9QG>3EAD2/1&I]0MZD=T]>G%?=3.@F>"D)MIFZ2;Q4:O;'<W%==JYB<K
MJFQLNPK]G!,]6H=4WVX:B73>G3%EUK'VN82)Z*HF)88HN"#YL56M[^ZN3N^E
M;P[61;78VK=GU[]=+Y4N)C;C.UQI!V/,FW ;I;W3R.@NW!=^&U,47!-BI4-V
MY?V[4I2U1J6+%K:[Q.,(^G-+#YDCUAK8+198TJ&B.R;@*%$S=$1P15,DY<,R
M;*N[S>JU!2CBY9'.Z=TR5^ZXRP4,R-! XLN1!N8RRS'@8P\PH>5?L\N7Y,<:
MI*&\:U5\#IN[TY2]/3_=_N=7$I+ADT_]XJ"SLI^T*WB@9LP;L:TZFI/1JYB3
MH>C[VCE,EJC6MSE7)FPZ7)3EYD%Z4"(J8HFT1545,!^D56-UO)2DK=K,J;+I
M<(VW>W&$>")M9(<Z);VVI\LILO#%Y\D1$4EY!1$38E=2S%QC1NK.)>E&4VX*
MD2@O%-\5:*_+/^W:J_M>5E'<9HMCB>UQ.>@0X^@G(C$A]W).E2,.L::5-AMY
MD(,$7I;%7F2J]MQ^HFGJX%/:O/CCPYB-ZAD:R8OL9MT F025"1,Z[,6S3'*J
M[,1P5*LPT3PI0@EKCC4RG&'B3KBW6/2.M-.3W(=GN[(+-@9&S%'E1'4%2(27
MTAS#L7DK6S;BVT\S:Y-X-9$DXV<3YUFX=6FYZ<E+'N%^<86"\ B9(T0=:>"$
MA)NP'=RUI9M5DTS:[<I'#B<?#_Q-N6H])W@]2RUD7*RO$<F08B!>S$"F*J(H
M*>BH&FZLW[2C+#B+-RJQ*H:XS\42MLK6!79Q+*U?(\1J#U3.0F70?D.-9LF;
MT6V@'?RU/Z$:Z>-"'U99\*EV\'Y4>T1+CHZ<:,WJV3'C)D_1)YEXLX/!CTD5
M.:H+^+U+(QM/+'0\T3TKY: NK5I*8TES> G6H>9.L4 Z19?EJ#2Z5+>M5I7$
MA7!-$_=FY<_WQ/\ [1*FW'-X%79/R/\ J9PL<V/8N*>HH-S-(_[P#'F6J0XN
M4'>J;ZMQH279F%>2LR6J"IP$'HNRK]5"2:YU):[%IJ;+G.BF9DVX["[3><,5
M$&P'>6*K45N+<B:]<48NI$"T=<"X&,6=X%"ZPH8S& ^D#[1K( ?.G1J7U%ZM
M2OZ3=BG$[-#W1O6FK"U+AGAVNVL0F$7=[5+%'97YJ8!2ZM$:=K_X,V9>I/5V
M*G\2,RA<90^%>*HKM\;6./\ XEQ5F+\@J*C4N?W/E^)"\/M?]OP)?K]]JR:P
MTGJ.4"#9HA2(,I_#T8ZR@06G"YAQ'#&H;6,9+BR>_P"6<9/E52=N7& W#6:Y
M):&&@YUD*8HWEPQS9\<,*AH\BUK5*U*PT'<HNI[_ ,0)5OV1IW4-1G%11SHC
M)MBY@NWTL,?-4F[MOTU'C0K["\O7<N"<3YPXU-;K![;:KPJPW.MS]8:+@A(F
M4@+!,4W;*\UTW<1M5A/RNI[3K6TGN--VUYHTX$S+5MAO$*ZQ;?)1UUB,ZJI@
MHYAR+Z08[T3<M=3\U;N1DHNM$SB2V5VS*$IQHFT1[@S[JN/]>']"J/1>27>=
M7_)7]V/])Y(>SC&]YS_Y=*TA^M9+=_\ F1^.)AKW:(<?7<N/>GW8<*69.M2F
M^9S:*JJHNS'8O-5:]94=PU-Z4^);V^YE/9Q=J*G*.#3.^XV+A]&=89.^R9/7
M$B*K.1T01?I%@FS^6I+NWVZ:CKDZ^)!9WF[:<HVHQT_*AD.)%D<@6VQR8V9^
M);@1@C+;L11(%+#ZV&%2]2LN,8-8J)%T7=*=RY&6$IDF:XF:46W#*.5D=RHI
M1,I*ZA<J(F&"_/5Z/4;.C54Y3Z/N5/3I\>'^I%^*<N+.6Q28[B/1GT,@,=RB
MI!7/ZJU)P[&=?H$90]5/-'E>9F: U.$IMM7[5,3*)*F)=6JHI!CR&/X4J-Q>
MTNJ6<62QE'J.W<<KL/Q+7@SHLZ(U*BN(ZP\*$V:<J+7H+<U):EDSR<[<H2TR
MP:->O%+\5:*_+/\ MV:O[7ED4]QFAXC-47D]=672+]T=L>F93;3DV6TI"A(Z
MZH..'EP4A;$>CNYZQMXK2W2K%U^9(A7%;1O"'3NG&BTW?7;SJ!]UO#"2W(!&
M415<-Q&QP''8B8K4UBY.4L5@1W812P>);<G2O[S>&B! ;#/+9M;,R&G+UT=.
ML1$_*%%'Y:K*>FX3Z:P*@X:3)VN]5Z"TU*%3@:8%UYS-M0FVW.O3'Y@;JS<6
MA-]I!!N32[#MXD2)_#G7NM;;"!0@ZIAEU.5<J"W*-'")/R"ZT/EK%M*<4WP$
M_*VNTL;_ -6+_P#FG[JZG_JO4_?F7E]H[7+Y^H]"H?5^[4E]/[=#V>(#OEM[
MCT5Z'O3]7]G6=L4]_G\5.KP_>^+EW3H)V_O3?R_9_P U;;G+XH-EG\5)SP?^
M'KAV/O:;W?H]HF_UN>H+V:[BUM>5][_:>#CK\(C[N[9._P#:[OV7[2L[?,CW
MV7 J?AE\;VWNW23WWT_^%^TYJM7N7^!3L\R_>;.EV3F[<O2W;N6N>CM2R*^X
M&?",GNGO"1W+H_1Z7E_%4VXS\"KL^5]YQN7\=+7W/W6YTN]?3W?W;L:+VV8E
M[R[B7ZP^&;CW/L"]X]T_6^K4-O,FNY&JD7OK/=^V3O'NCI?T.:NF\OBIQ?J^
M*&P'#OXJU9W+]A[CT.[\GJ_5\E4IY(Z=K.67 P_%3WL/<NBG0[S^M\G-7E>K
M\RY3W7^/Y?7^X[>'?NV[=Q[L[N[ST5Z7J<]2=-]N7+D\LR+K?NQY\UGEX&8X
M2>[9_8]L'8;NARU:Z1RO+P*77O<CGEQ[SS1OXLN]AO/^M[!*TC^J>1)=_0+/
M/P/?Q2]SM=RZ7[5VOZGR\]2]3Y/I\2'H/N_7_;EXD"T'\0QNY=).]?[OU^:N
M+TSW/I/1=:]GZ_#+Q+GO/NF1V'9KWKL-WT_)7J;W+P\3P]CG6?AF4$7O%>Y]
M/D[O_DUX[_UX?N/HD?:^O+Q)OK?N6G>X] NS['I#V7DKK[[*&1YWIF=WF^.T
MDW$KX8_9NT;[S_B>M^*KW4?:X>)0Z-^H7-QY3KX6>X'>CVY=GV6Y.A^.M>F>
MV:]8][XKXE:>)3XETAW+IGWOI=LUT*[>WR9P[V:/5XJOAVW>[.U/O??=R=U]
M7Z_R5G:Y\33<%):4^ M2^Y.E&[QWWMAW?9<_EPJW+G69#'EX&V?"_P#AGI[L
MO=[79=CT>3U:YUWF?>78<I2OAM_B)>?=?='NY]IW@>CZO/5B_P J(;69W^)[
GXLL'NSNI=][3M^7U/YZQM^5F;V9L/_VW_-]C^JZ']'\55>)/P/_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
